Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
QuintilesIMS
Julphar
McKinsey
Cerilliant
Baxter
Queensland Health
McKesson
US Department of Justice

Generated: February 23, 2018

DrugPatentWatch Database Preview

Daiichi Sankyo Company Profile

« Back to Dashboard

Summary for Daiichi Sankyo
International Patents:163
US Patents:4
Tradenames:9
Ingredients:9
NDAs:11

Drugs and US Patents for Daiichi Sankyo

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-003 Apr 20, 2017 RX No No 7,955,619 ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-002 Sep 26, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up
Daiichi Sankyo Inc ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-001 Apr 20, 2017 RX No No 7,955,619 ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes 9,149,532 ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 RX Yes No 7,955,619 ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo TRIBENZOR amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200175-003 Jul 23, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-002 Jan 8, 2015 RX Yes No ➤ Sign Up ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride TABLET;ORAL 021176-001 May 26, 2000 RX Yes Yes 7,229,613*PED ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 RX Yes No 7,955,619 ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo TRIBENZOR amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200175-004 Jul 23, 2010 AB RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Daiichi Sankyo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-002 Oct 2, 2009 7,101,960*PED ➤ Sign Up
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 5,580,880 ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-001 Oct 2, 2009 6,066,678*PED ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-002 Oct 2, 2009 5,607,669*PED ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride CAPSULE;ORAL 021141-001 May 26, 2000 5,607,669*PED ➤ Sign Up
Daiichi Sankyo TRIBENZOR amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200175-001 Jul 23, 2010 5,616,599*PED ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride CAPSULE;ORAL 021141-001 May 26, 2000 5,693,675*PED ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-001 Oct 2, 2009 5,607,669*PED ➤ Sign Up
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-002 Oct 2, 2009 5,919,832*PED ➤ Sign Up
Daiichi Sankyo Inc EVOXAC cevimeline hydrochloride CAPSULE;ORAL 020989-002 Jan 11, 2000 4,855,290 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Powder for Oral Suspension 1.875 g/Packet and 3.75 g/Packet ➤ Subscribe 4/9/2010
➤ Subscribe Tablets 625 mg ➤ Subscribe 7/1/2009
➤ Subscribe Capsules 30 mg ➤ Subscribe 2/27/2009
➤ Subscribe Tablets 10 mg/20 mg and 5 mg/40 mg ➤ Subscribe 3/31/2008
➤ Subscribe Tablets 5 mg/20 mg and 10 mg/40 mg ➤ Subscribe 2/11/2008
➤ Subscribe Tablets 20 mg/12.5 mg ➤ Subscribe 5/11/2007
➤ Subscribe Tablets 40 mg/12.5 mg and 40 mg/25 mL ➤ Subscribe 2/15/2007
➤ Subscribe Tablets 5 mg, 20 mg and 40 mg ➤ Subscribe 4/25/2006

Non-Orange Book US Patents for Daiichi Sankyo

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,261,880 Methods of treating Syndrome X with aliphatic polyamines ➤ Sign Up
7,342,014 Diamine derivatives ➤ Sign Up
9,707,296 Pharmaceutical composition ➤ Sign Up
7,541,024 Low salt forms of polyallylamine ➤ Sign Up
8,377,428 Low salt forms of polyallylamine ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Daiichi Sankyo Drugs

Supplementary Protection Certificates for Daiichi Sankyo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030 France ➤ Sign Up PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
00478 Netherlands ➤ Sign Up PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
C0009 Belgium ➤ Sign Up PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
2015000077 Germany ➤ Sign Up PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
292 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
2011 00026 Denmark ➤ Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2015 00052 Denmark ➤ Sign Up PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
00625 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
00499 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
00133 Netherlands ➤ Sign Up PRODUCT NAME: OLMESARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN DE CARBOXYGROEP GEKOZEN UIT DE VOLGENDE : EEN ALKYLGROEP 1-4 KOOLSTOFATOMEN, EEN BENZYLGROEP, EEN ALKANOYLOXYALKYLGROEP WAARIN HET ALKANOYLDEEL 1-5; NATL. REGISTRATION NO/DATE: RVG 28785-RVG 28787 20030527; FIRST REGISTRATION: DE 502.02.00.00,502.02.01.00, 502.02.02.00 20020813
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Johnson and Johnson
Chubb
QuintilesIMS
Accenture
Colorcon
McKinsey
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot